Matrix-Bio's goal is to be a leading provider of metabolite-based testing in the fast-growing molecular diagnostic testing market. The company's first product, MetaMarker-BCR, for detecting breast cancer recurrence monitoring is is is being commercialized as the first metabolite-based commercial test in the world. Its early breast cancer detection test, MetaMarker-BCD, will follow.